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Abstract
Both in humans and animal models, an acute increase in plasma insulin levels, typically following meals, leads to transient
depression of hepatic secretion of very low density lipoproteins (VLDL). One contributing mechanism for the decrease in
VLDL secretion is enhanced degradation of apolipoprotein B100 (apoB100), which is required for VLDL formation. Unlike the
degradation of nascent apoB100, which occurs in the endoplasmic reticulum (ER), insulin-stimulated apoB100 degradation
occurs post-ER and is inhibited by pan-phosphatidylinositol (PI)3-kinase inhibitors. It is unclear, however, which of the three
classes of PI3-kinases is required for insulin-stimulated apoB100 degradation, as well as the proteolytic machinery
underlying this response. Class III PI3-kinase is not activated by insulin, but the other two classes are. By using a class I-
specific inhibitor and siRNA to the major class II isoform in liver, we now show that it is class II PI3-kinase that is required for
insulin-stimulated apoB100 degradation in primary mouse hepatocytes. Because the insulin-stimulated process resembles
other examples of apoB100 post-ER proteolysis mediated by autophagy, we hypothesized that the effects of insulin in
autophagy-deficient mouse primary hepatocytes would be attenuated. Indeed, apoB100 degradation in response to insulin
was significantly impaired in two types of autophagy-deficient hepatocytes. Together, our data demonstrate that insulin-
stimulated apoB100 degradation in the liver requires both class II PI3-kinase activity and autophagy.
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Introduction
ApoB100 is required in the liver for the assembly and secretion
of very low density lipoproteins (VLDL), the precursors of low
density lipoproteins (LDL). Both VLDL and LDL are atherogenic,
and one of the statistically strongest risk factors for coronary artery
disease is the plasma level of apoB100 (e.g., [1]). The fundamental
importance of apoB100 to the biogenesis of VLDL and to
atherosclerosis has stimulated considerable investigations on its
metabolism. A major insight into apoB100 metabolism came in
the mid-1980s with pioneering studies by Dr. Roger Davis, who
used rat primary hepatocytes, and by Dr. Sven Olof-Olofsson,
who employed human HepG2 cells [2,3]. These investigators
showed that a substantial amount of newly synthesized protein was
subject to degradation. In contrast to most hepatic secretory
proteins, in which the amount of secreted protein is tightly linked
to the amount that is synthesized, variations in hepatic apoB100
and VLDL secretion were linked instead to the rate of apoB100
intracellular degradation (reviewed in [4]).
One of the metabolic signals that reduce VLDL secretion is
insulin. For example, during acute hyperinsulinemia, such as
occurs in the post-prandial state, hepatic VLDL triacylglyceride
(TG) production becomes transiently depressed in humans (e.g.,
[5]) and in rodent models (e.g., [6]). It was proposed that one basis
for this depression was insulin triggering a decrease in the amount
of apoB100 that was available for VLDL assembly. Indeed, it was
subsequently shown in model systems (typically, rodent primary
hepatocytes) that an acute exposure to portal vein insulin levels (to
simulate the post-prandial state) reduced cellular levels of
apoB100, an effect largely attributable to its degradation (e.g., [7]).
It is now appreciated that the degradation of pre-secretory
hepatic apoB100 occurs via at least two distinct pathways
(reviewed in [4,8]). One pathway is ER-associated degradation
(ERAD), which requires the ubiquitin-proteasome system. During
this process, nascent apoB100 that is insufficiently lipidated during
its translation and translocation is recognized by cytoplasmic and
ER lumenal molecular chaperones, which then deliver the protein
for ubiquitinylation and degradation. The second pathway has
been termed post-ER, pre-secretory proteolysis (PERPP), and was
first described in studies on the effects of fish oil fatty acids on
hepatic apoB100 and VLDL production [9]. In this case, and in
two other examples of apoB100 PERPP (human apoB100 mutant
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A31P and glucosamine-induced apoB100 degradation), evidence
has been presented to implicate autophagy as the culprit
responsible for the proteolytic process [10–12]. Because insulin-
induced apoB100 degradation is also a post-ER process [13], we
hypothesized that insulin also directs apoB100 for degradation via
autophagy.
In this report, we provide data using primary mouse hepatocytes
to support this hypothesis. Furthermore, because PI3-kinases can
regulate autophagy [14–16], and because insulin-mediated
apoB100 degradation is compromised by non-specific PI3-kinase
inhibitors, such as wortmannin (e.g., [17]), we also sought to
determine which specific PI3-kinase class triggered the autophagic
destruction of apoB100. By using a variety of methods, we have
established that the class II PI3-kinase mediates this event. Besides
providing new insights into the fundamental processes of VLDL
assembly and secretion, our data also provide a molecular basis for
the observed increase in apoB100 and VLDL production in
insulin-resistant individuals, and suggest future therapeutic
avenues to overcome the accompanying risk of cardiovascular
disease in these individuals.
Materials and Methods
Reagents
Protease inhibitor cocktail tablets were obtained from Roche
(Indianapolis, IN) or Sigma-Aldrich (St. Louis, MO). Protein A -
Sepharose was obtained from GE Healthcare (Uppsala, Sweden)
or Invitrogen (Frederick, MD). [35S]-methionine/cysteine protein
labeling mix was obtained from Perkin Elmer Life Sciences
(Waltham, MA). Goat anti-mouse apoB polyclonal antibody was a
gift of Dr. Kevin J. Williams (Department of Medicine, Temple
University) and was previously characterized [18]. The PI3-kinase
inhibitor wortmannin was purchased from Sigma-Aldrich (St.
Louis, MO). The class I-specific PI3-kinase inhibitor PIK-75 was
purchased from Cayman Chemical (Ann Arbor, MI). The insulin
was from Sigma-Aldrich (St. Louis, MO).
Animals and primary hepatocyte culture
All animal procedures were approved by the Institutional
Animal Care and Use Committee, NYU School of Medicine.
Mice deficient in APOBEC1 (Apobec12/2) on a C57BL6
background were provided by Dr. Janet Sparks (University of
Rochester) with permission from Dr. Nicholas Davidson (Wash-
ington University; [19]). Mice normally synthesize both apoB100
and apoB48 in their livers. The deletion of the apoB mRNA
editing enzyme 1 (APOBEC1), which generates a mRNA
encoding apoB48 from the apoB100 transcript, results in the
production of only apoB100, the form secreted by human liver
[20,21]. Atg5 is an essential autophagy factor [14]. Atg5-floxed
mice [22] were given to us by Dr. Steven Burden (NYU School of
Medicine) with permission from Dr. Noboru Mizushima (Tokyo
Medical and Dental University) and crossed with Alb-Cre mice
(mice with the Cre-recombinase gene driven by the albumin
promoter; Jackson Laboratory}) to generate liver specific Atg5-
deficient mice. The genotyping of the Atg5-floxed mice was
performed as previously described [23]. The genotyping of Alb-Cre
mice was performed according to the protocol described by the
Jackson Laboratory. In some experiments, hepatocytes were
isolated from mice with either the floxed or the deleted Atg5 allele
that were crossed with Apobec12/2 mice.
Mouse primary hepatocytes were prepared by perfusion of livers
with collagenase I (Worthington Biochemical) or Liberase TM
(Roche). Hepatocytes were maintained in Waymouth’s medium
(Waymouth’s MB 752/1, containing 1% streptomycin/penicillin,
1% L-glutamine, 0.2% BSA, and 0.1 nM insulin). After a 12–14 h
incubation, the primary hepatocytes were subjected to study
protocols.
Pulse-chase metabolic labeling experiments
Portal levels of post-prandial insulin can achieve concentrations
in excess of 100 nM. After pilot dose-response studies, protocols
were designed so that primary hepatocytes were treated with
100 nM of insulin. In some experiments, there was co-treatment
with wortmannin (100 nM) or the class I PI3-kinase specific
inhibitor PIK75 (100 nM; [24]). The various treatment media
were applied to the cells, which were then pulse-labeled with
240 mCi/ml [35S]-protein labeling mix for 15 min, and chased for
30 min and 120 min in non-radioactive medium with excess
methionine (1.5 mg/ml) and cysteine (0.5 mg/ml). The first chase
point was chosen according to the difference in apoB100
translation efficiency in different hepatic cells [10,25]. The
metabolic treatments were continued in the chase period. At the
end of the chase, cells and conditioned medium were collected.
[35S]-labeled apoB100 from cell lysate and conditioned medium
was immunoprecipitated, separated by 4% SDS-PAGE, and then
visualized using a phosphorImager (Trio Typhoon; Amersham,
GE healthcare), with quantification by densitometry of the
apoB100 bands. Total labeled apoB100 protein recovery was
normalized to the amount of total labeled protein that was
precipitated with trichloroacetic acid (TCA).
PI(3,4)P2 quantification
Cellular PI(3,4)P2 concentrations were measured by using anti-
PI(3,4)P2 mouse monoclonal antibody (Echelon Biosciences)
following manufacturer’s instructions. Briefly, cells were collected
in ice-cold 0.5 M TCA, and the pellet was washed in 5% TCA
with 1.0 mM EDTA. Neutral lipids and acidic lipids were
extracted sequentially by adding MeOH:CHCl3 (2:1) and
MeOH:CHCl3:12 M HCl (80:40:1), and acidic lipids were
collected by phase separation in 0.75 mL of CHCl3 and
1.35 mL of 0.1 M HCl. PI(3,4)P2 was quantified by dot blotting
using anti-PI(3,4)P2 mouse monoclonal antibody.
siRNA treatment of hepatic cells
For siRNA experiments, cells were treated for 48 h with
SiGenomeH pools (for control siRNAs or ones specific for mouse
PI3-kinase CII gamma or PI3-kinase CIII (Vps34); Dharmacon,
Thermo Fisher Scientific) and the DharmaFECT 4 transfection
reagent (Dharmacon, Thermo Fisher Scientific) according to the
manufacturer’s protocol. Pulse-chase experiments were performed
as described above. The efficiency of PI3-kinase knockdown in
mouse primary hepatocytes was assessed by a two step RT-PCR
protocol using the ABsolute Blue SYBR Green Mix from Thermo
Scientific and the following primers: ATTTCCTCACTGGTGG-
CATC (forward) and GAGCCTCGAGTCCTCATACG (reverse)
for PI3-kinase CII gamma, CGAGGGAGCAGGAACATCA
(forward) and TGTGCGGCATAGACAGTGAAC (reverse) for
PI3-kinase CII alpha, CCCTCGAACCTATACTTCTCGA-
TATG (forward) and TGGCCATTGGCAACAGTGT (reverse)
for PI3-kinase CII beta, and GGCACCCAGAGTGAGCAGTAC
(forward) and CAGGTGGAGGAAGGCTGTGT (reverse) for
PI3-kinase CIII .
LC3 Western Blot
Primary hepatocytes were prepared as described previously
[22]. Total protein was extracted using RIPA buffer (50 mM Tris,
pH 7.4, 150 mM sodium chloride, 0.25% sodium deoxycholate,
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1% Nonidet P-40) and 50 mg was used for Western Blot analysis
using rabbit polyclonal anti-LC3 antibody (dilution 1/500) from
Novus Biological. Mouse monoclonal anti-GAPDH antibody
(dilution 1/5000) was used as a loading control (Millipore).
Lipoprotein fractionation
Primary hepatocytes were radiolabeled with 100 mCi/ml [35S]-
Met/Cys for 4 h. Lipoproteins in the conditioned medium were
separated by cumulative rate flotation (density gradient) ultracen-
trifugation. Briefly, 4 ml of the sample, adjusted to d= 1.10 g/ml
with solid KBr, were overlaid with 3 ml of d= 1.065 g/ml KBr,
3 ml of d= 1.02 g/ml KBr, and 3 ml of d = 1.006 g/ml KBr in a
Beckman SW41 centrifuge tube. After centrifugation at 37,000
rpm for 18 h at 15uC, VLDL and the other lipoproteins were
collected from the top into 12 one-ml fractions. ApoB100 in
individual fractions or pooled fractions was immunoprecipitated,
resolved by SDS-PAGE, and visualized using a phosphorImager
(Trio Typhoon; Amersham, GE Healthcare), with quantification
by densitometry of the apoB100 bands.
Statistical analyses
All experiments were conducted in triplicate at least two times.
Data are typically expressed as the mean6SEM. Statistical
differences were analyzed using GraphPad Prism software
(GraphPad Software Inc., San Diego, CA) using an unpaired T
test. Data in which more than two groups were compared were
analyzed by ANOVA with post-hoc testing. A P value of less than
0.05 was considered significant and is indicated by *; p,0.01 is
indicated by **, and p,0.001 by ***. Where displayed, NS denotes
not significant.
Results
Roles of specific PI3-kinases in insulin-stimulated
apoB100 degradation in primary hepatocytes
Mouse and rat primary hepatocytes secrete both apoB100 and
apoB48-containing lipoproteins. In human liver, however, only
apoB100 is secreted (and is exclusively associated with VLDL)
because of the lack of the apoB mRNA editing activity that is
required for apoB48 production. Given the greater relevance of
apoB100 to human liver physiology, we wished to focus on this
isoform. The major form of apoB in rodent liver is normally
apoB48, and the sparseness of apoB100 hampers its accurate
detection. To overcome this limitation, we turned to mice deficient
in the apoB mRNA editing activity (Apobec-12/2;[19]), in which
mouse liver is ‘‘humanized’’ to produce only apoB100. Note that
the effects of insulin on apoB100 are independent of the presence
or the absence of hepatic apoB48 production (e.g., [7], [26], and
data below).
As shown in Figure 1A and 1B, we observed an increase in
apoB100 degradation (reflected by a decrease in apoB100
recovery) in cells treated with insulin that was dependent on
PI3-kinase activity, consistent with previous data [26]. Interest-
ingly, when the cells were treated with insulin and the pan PI3-
kinase inhibitor (wortmannin) or with wortmannin alone, apoB100
recovery rose. These combined results suggest that a PI3-kinase
regulates a degradative process that is both insulin-stimulated and
that occurs at a lower level during the basal turnover of apoB100.
Because wortmannin is a pan PI3-kinase inhibitor, we next
wished to establish which specific enzyme class mediated these
effects. Class III PI3K is not known to be a target of insulin
signaling [15], so we considered the other two classes. We began
by using an established class I-specific inhibitor, PIK75 [24]. As
shown in Figure 2A and 2B, PIK75 did not prevent apoB100
degradation stimulated by insulin; rather, we observed a trend
toward an enhancement of the insulin effect. Relevant to the
autophagy studies, below, this result is consistent with the finding
that class I PI-3 kinase activity is a negative regulator of autophagy
[14].
Like the class I enzymes, class II PI3-kinases have been shown
responsive to insulin stimuli [27], so we then assessed the role of
class II PI3-kinase on apoB100 degradation after insulin addition.
We first established that class II activity was stimulated by insulin
by measuring the production of one of its specific products,
PI(3,4)P2. As shown in Figure 3, we observed a strong and
transient increase of PI(3,4)P2 upon insulin stimulation, as
anticipated from published results [27].
Due to the absence of a specific inhibitor of the class II PI3-
kinase, we instead used siRNA to knock down the major PI3-
kinase class II isoform present in the liver [28–30], PI3-kinase class
II gamma, and examined the impact on the insulin response. The
siRNA directed against this class II isoform suppressed its RNA
levels by 90% (Figure 4A). Also, by using a functional assay to
measure its specific product, PI(3,4)P2 after insulin stimulation, we
observed nearly complete abolition of PI3-kinase class II gamma
activity in the silenced hepatocytes (Figure S1). Even though the
gamma isoform is highly related to the alpha and beta isoforms,
the targeted siRNA was without a significant effect on their
mRNA levels (Figure 4B and 4C), thus confirming the specificity of
Figure 1. Insulin-stimulated apoB100 degradation in mouse
primary hepatocytes is PI3-kinase- dependent. A) Primary
hepatocytes from Apobec12/2 mice (which only synthesize apoB100)
were incubated in media containing (INS) or lacking (CONT) insulin and/
or wortmannin (WORT) and were pulse labeled for 15 min with [35S]-
protein labeling mix and chased in non-radioactive medium for 30 and
120 min with the treatments maintained. ApoB100 was then immuno-
precipitated and separated by SDS-PAGE and quantified as described in
Materials and Methods. The histogram (mean6SEM) represents the
results from 2 independent experiments, each performed in triplicate.
B) Representative primary data of the experiments summarized in panel
A; ** indicates P,0.01.
doi:10.1371/journal.pone.0057590.g001
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the siRNA. Notably, as shown in Figure 4D and E, insulin-
stimulated apoB100 degradation was completely abrogated by
knocking down the gamma isoform of class II PI-3 kinase, thereby
demonstrating its key role in this process.
Insulin-stimulated apoB100 degradation requires
autophagy
Insulin stimulates a form of apoB100 degradation that is a pre-
secretory, but a post-ER process [13]. We previously showed that
omega-3 fatty acids (e.g., docosahexaenoic acid; DHA) stimulate
apoB100 degradation [31], also by a post-ER, pre-secretory
proteolysis process (PERPP; [9]. PERPP-mediated turnover of
apoB100 was subsequently found to be through the autophagy
pathway [10]. The broad similarities between insulin and DHA-
stimulated apoB100 degradation raised the issue of whether the
effect of insulin on apoB100 degradation also involved autophagy.
To directly test this hypothesis, experiments were conducted in
primary hepatocytes from Atg5-deficient mice [22]. Atg5 partic-
ipates in the early steps in the formation of autophagosomes [14].
To create mice with a liver-specific deficiency of Atg5 (designated
as Atg52/2 in Figure 5), we crossed mice having floxed alleles of
Atg5 with Alb-Cre mice expressing Cre-recombinase driven by the
albumin promoter [32]. Atg5-floxed mice were used as sources of
control hepatocytes (Atg5+/+ in Figure 5). Autophagic activity was
examined in the control and liver-specific Atg5-deficient mice by
assaying for the lipidation of the autophagosomal membrane
protein, LC3 to the form called LC3-II, which is associated with
autophagosomes [33]. As shown in Figure 5A, LC3-II was evident
only in the control (Atg5+/+) hepatocytes, and the amount
increased when lysosomal degradation was inhibited by NH4Cl
and E64D (‘‘+’’). This increase was expected because after
autophagosomes fuse with lysosomes, LC3-II is degraded. In
contrast, only the LC3 precursor (LC3-I) was evident in the Atg52/2
hepatocytes, regardless of whether lysosomal degradation had been
inhibited, indicating the lack of autophagosome formation. These
data confirm that the autophagy pathway is inactive in the Atg52/2
hepatocytes. We then assessed the impact of insulin-stimulated
apoB100 degradation in these cells. In the Atg5+/+ hepatocytes there
was the expected decrease in apoB100 recovery from insulin-treated
cells (Figure 5B). In contrast, in the Atg5-deficient hepatocytes,
insulin treatment had no effect on apoB100 recovery.
Independent confirmation for a role for autophagy in insulin-
stimulated apoB100 degradation came from studies of class III
PI3-kinase, which as noted earlier, is not a target of insulin [15].
Class III PI3-kinase (also called Vps34 or PIK3C3), however, plays
a critical general role in autophagy in most cell types [14],
including liver [34]. Therefore, if autophagy were involved in
insulin-stimulated apoB100 degradation, silencing of Vps34 should
have an effect on this process. This expectation was confirmed by
pulse-chase studies after siRNA knock down of Vps34 (Figure S2).
To establish that the loss of insulin-stimulated degradation of
apoB100 was associated with a general effect of the Vps34 knock
down on autophagy, we assessed the level of general autophagic
activity by measuring (by western blot) the active, lipidated form of
the autophagosome protein LC3 (LC3-II; [33]). As shown in
Figure S2, knock-down of Vps34, but not of PI3-kinase class II
gamma, increased the level of LC3-II, reflecting a reduction in
general autophagic activity [34].
Insulin-stimulated apoB100 effects have been reported to be
preferential for apoB100 normally associated with the more
Figure 2. Class I PI3-kinase activity is dispensable for insulin-
stimulated apoB100 degradation in mouse primary hepato-
cytes. A) Experiments were performed as in Figure 1, but in the
presence or absence of the class I specific PI3-kinase inhibitor, PIK75.
The histogram (mean6SEM) represents the results from 2 independent
experiments, each performed in triplicate. B) Representative primary
data of the experiments summarized in panel A.
doi:10.1371/journal.pone.0057590.g002
Figure 3. Insulin stimulates class II PI-3 kinase activity in mouse
primary hepatocytes. Primary hepatocytes from Apobec12/2 mice
were cultured in serum free conditions for 16 h before the addition of
insulin to a final concentration of 100 nM. At the indicated times, the
cells were harvested in ice cold 0.5 M TCA, and acidic lipids were
extracted. PI(3,4)P2 concentrations were measured by dot blotting
using anti-PI(3,4)P2 antibody (n = 3 at each time point). Data represent
the mean6SEM.
doi:10.1371/journal.pone.0057590.g003
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lipidated particles (e.g., VLDL [35]). Therefore, we performed a
gradient density analysis of lipoproteins secreted from primary
hepatocytes of Apobec12/2 mice that had been incubated in the
presence or absence of insulin. As expected, we observed that
insulin treatment decreased the recovery of apoB100 normally
associated with the largest (highly lipidated) particles (density
fraction 1.003; Figure 5C). In contrast, the effect of insulin
treatment on apoB100 depletion in the density fractions normally
containing these highly lipidated particles was lost in Apobec12/2
hepatocytes deficient in Atg5 (Figure 5D). Overall, these data
strongly suggest that apoB100 normally associated with highly
lipidated apoB-lipoproteins, including VLDL, is targeted for
insulin-stimulated degradation via the autophagic pathway.
Discussion
There are two major findings in this report on the mechanisms
underlying insulin-stimulated degradation of apoB100, namely,
that the process 1) requires autophagy, and, 2) depends on the
gamma isoform of the class II PI3-kinase. In addition, we provide
evidence that autophagy also contributes to basal apoB100
turnover, for which other classes of PI3-kinases may also play a
role.
We and others previously reported that autophagy is critical
during other examples of induced apoB100 post-ER, pre-secretory
proteolysis (PERPP). Notably, PERPP mediates the degradation of
apoB100 in the presence of fish oils or glucosamine [9,12], or
when the apolipoprotein contains a specific structural mutation
[11]. In these cases, there is sufficient lipidation for pre-VLDL
particles to form, but there is aberrant post-ER maturation to fully
lipidate VLDL. That autophagy is an important disposal process
for apoB100 in these examples is consistent with at least two lines
of reasoning. First, VLDL assembly is a prolonged process that
begins in the ER and continues post-ER through the intermediate
compartment and in the Golgi (reviewed in [36–38]). Thus, unlike
the majority of secretory proteins in which quality control is
exerted primarily at the ER level [39,40], the maturation of
apoB100-containing particles is subject to multiple checkpoints,
Figure 4. Insulin-stimulated apoB100 degradation in mouse primary hepatocytes is dependent on class II PI3-kinase gamma.
Primary hepatocytes from Apobec12/2 mice were transfected with control (scrambled) siRNA or class II PI3-kinase (PIK3C2c) specific siRNA. After a
total of 48 h after transfection, (A) PIK3C2c, (B) PIK3C2a, and (C) PIK3C2b mRNA levels were assessed by two-step qRT-PCR, and their abundance was
normalized to 28S rRNA. The histogram (mean6SEM) represents the results from 2 independent experiments, each one performed in triplicate. D)
Control or PIK3C2c siRNA transfected primary hepatocytes from Apobec12/2 mice were incubated in medium with (INS) or without (CONT) insulin,
pulse-labeled for 15 min with [35S]-protein labeling mix, and then chased for 30 and 120 min with the treatments maintained. Total apoB100
recovery and quantification were as in Figure 1. The histogram (mean6SEM) represents the results from 2 independent experiments, each one
performed in triplicate; ** and *** indicate P,0.01 and 0.001, respectively. E. Representative primary data of the experiments summarized in panel D.
doi:10.1371/journal.pone.0057590.g004
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including important steps beyond the ER. Second, the autophagic
process is specialized to degrade substrates of enormous size,
including whole organelles [14], and so it makes sense that
incompletely formed or abnormal VLDL particles (e.g., containing
aggregated apoB100; [10]) will need to employ a disposal route
that can accommodate substrates far bigger than typical secretory
proteins.
Despite the expanding evidence for autophagy being a final
common pathway for the degradation of apoB100 that has
progressed past the ER, it remains mysterious how apoB100 or its
associated lipoprotein particles are identified for disposal. During
autophagy, the molecular features underlying how specific
substrates are recognized are poorly defined [41]. As implied
above, we favor a scenario in which a failure to fully lipidate pre-
VLDL to the mature form in a post-ER compartment targets the
intermediate particles for autophagy. This is based on the finding
that during the fish oil and insulin-stimulated autophagic
degradation of apoB100, as well as the autophagic destruction of
A31P mutant apoB100, pre-VLDL particles are formed and reach
the Golgi, but VLDL maturation is impaired (V. Maitin, U.
Andreo, E. Fisher, unpublished results, [35], and [11], respective-
ly).
Another novel aspect of this study is the involvement of class II
PI3-kinase in insulin-stimulated apoB100 degradation, which
appears to be the first link of this class of PI3-kinases to autophagy.
We were led to investigate PI3-kinases because the pan-PI3-kinase
Figure 5. Effects of insulin on apoB100 degradation and VLDL-apoB100 secretion are blunted in autophagy-deficient mouse
primary hepatocytes. Primary hepatocytes were isolated from mice with floxed alleles of Atg5 (Atg5+/+) or Atg5f/f x Alb-Cre (Atg52/2) mice (i.e., mice
with hepatic deficiency of Atg5), and cultured in serum-free conditions for 16 h before insulin addition. A) A western-blot for LC3 was performed with
lysates of primary hepatocytes from Atg5+/+ or Atg52/2 mice; ‘‘(+)’’ represents the condition in which lysosomal degradation has been blocked
(20 mM NH4Cl + 10 mM E64D) to increase LC3 recovery and ‘‘(-)’’ represents untreated cells. When autophagy is active, LC3 (‘‘LC3-I’’) is lipidated to
form LC3-II. GAPDH was used as the loading control. B) Primary hepatocytes from Atg52/2 or Atg5+/+ mice were incubated in media with (INS) or
without insulin (CONT) and pulse-labeled for 15 min with [35S]-protein labeling mix, and were then chased for 30 and 120 min in non-radioactive
medium with the treatments maintained. Total apoB100 recovery and quantification were as in Figure 1. The histogram (mean6SEM) represents the
results from 2 independent experiments, each one performed in triplicate; ** indicates P,0.01. C) Primary hepatocytes from Apobec12/2 mice were
labeled with [35S]-protein labeling mix for 4 h in the presence (+ Insulin) or absence (2 Insulin) of 100 nM insulin. Conditional media samples were
collected and lipoproteins were separated by density gradient ultracentrifugation. ApoB100 in individual fractions was immunoprecipitated, resolved
by SDS-PAGE, and quantified by densitometry after bands were detected by a phosphorImager. The statistical significance of the comparisons
between the density profiles is based on 3 independent replicate experiments. D) An experiment similar to the one in panel C was performed, but
using Atg5-deficent primary hepatocytes prepared from Apobec12/2 mice.
doi:10.1371/journal.pone.0057590.g005
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inhibitor wortmannin had been shown to block insulin-stimulated
apoB100 degradation (e.g., [13][15]), as we also found (Figure 1).
As noted earlier, there are three major classes of PI3-kinases (see
[16] for a recent review). Class I contains the isoforms associated
with insulin-stimulated regulation of glucose metabolism, and has
been historically the pathway of interest in diabetes research.
Evidence against this class mediating insulin-stimulated apoB100
degradation, however, is that the signaling cascade initiated by
class I PI3-kinase inhibits autophagy through Akt-dependent
activation of mTOR [14]. Furthermore, it was shown that insulin-
mediated apoB100 degradation was Akt-independent [42].
Experimental confirmation for the lack of involvement of class I
PI3-kinase in insulin-stimulated apoB100 degradation was pro-
vided in the present study (Figure 2). Specifically, we found that a
class I-specific inhibitor did not block the insulin effect; instead,
apoB100 recovery tended to be decreased, most likely through
diminished mTOR activation, which resulted in increased
autophagy.
There is firm evidence that the action of class III PI3-kinase
increases general autophagy in most tissues (e.g., see [14]),
including liver [34]. Consistent with a role for autophagy in
insulin-stimulated apoB100 degradation, then, was our finding
that knocking down class III PI3-kinase prevented degradation
(Figure S2). The current understanding is that the product of the
PI3-kinase enzymatic reaction, PI(3)P, serves to promote the
formation of membrane-bound complexes that include the key
autophagy initiating factor beclin-1 [16]. There is no evidence,
however, that the activity of class III PI3-kinase is stimulated by
insulin [15,16]. In contrast, class II PI3-kinases are known to be
phosphorylated in response to insulin and other growth factors
[27]. There are three sub-classes of the class II isoform, namely
alpha, beta, and gamma. Gamma is the most abundant one in the
liver [28–30], explaining why we chose to manipulate the
expression of this isoform in the present studies.
Compared to classes I and III, relatively little is known about
the biological effects of the class II isoform. It is enriched in the
juxtanuclear Golgi in rat liver [29], and a proposed role for its
activity is to regulate vesicle traffic from the trans-Golgi network
[28]. Given that the insulin-stimulated effect on apoB100
degradation requires post-ER PI3-kinase dependent trafficking
[13], and that we have shown that fish oil-stimulated autophagy
requires trafficking from the Golgi [10], it is tempting to speculate
that a class II isoform mediates these transport events. It is unlikely
that insulin signaling through class II PI3-kinase is operating
through induction of Atg5 itself because in autophagy-competent
hepatocytes the level of Atg5 was unaltered after insulin
stimulation (L. Guo, E. Fisher, data not shown). Obviously,
further investigation will be needed to evaluate in depth the many
possible mechanisms underlying the class II PI3-kinase effects on
insulin-stimulated apoB100 degradation.
In conclusion, the present results indicate that autophagy and
class II PI3-kinase are required for the degradation of apoB100 in
insulin-stimulated hepatocytes. In insulin-resistant people,
apoB100 and VLDL are overproduced (e.g., [43,44]). Conse-
quently, our results suggest that this may represent the loss of the
insulin-stimulated autophagy-dependent pathway for apoB100.
This intriguing possibility can be indirectly tested by extending our
studies to insulin-resistant mice competent or deficient in
autophagy or class II PI3-kinase activity.
Supporting Information
Figure S1 Effect of siRNA knockdown of PI3K class II
gamma on the insulin-stimulated production of its
specific product PI(3,4)P2. Levels of PI(3,4)P2 were assessed
as in Figure 3 in primary hepatocytes (isolated from Apobec12/2
mice) treated with either control or class II PI3-kinase gamma
siRNA.
(TIF)
Figure S2 Class III PI3-kinase knockdown reduces
insulin-stimulated apoB100 degradation and autophagic
activity in mouse primary hepatocytes. A) Primary
hepatocytes (isolated from Apobec12/2 mice) were treated with
either control or Class III PI3-kinase (Vps34) siRNA. 48 h after
siRNA transfection, pulse-chase experiments were performed.
ApoB100 recovery results are represented in the histogram
(mean6SEM) from two independent experiments with each
performed in triplicate. B) Western blotting analysis of LC3-II
(normalized to GAPDH) in primary hepatocytes transfected with
control, PIK3C2gamma or PIK3C3 (Vps34) siRNA as in panel A.
(TIF)
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